Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 177

1.

Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.

Inoue S, Patil R, Portilla-Arias J, Ding H, Konda B, Espinoza A, Mongayt D, Markman JL, Elramsisy A, Phillips HW, Black KL, Holler E, Ljubimova JY.

PLoS One. 2012;7(2):e31070. doi: 10.1371/journal.pone.0031070. Epub 2012 Feb 15.

PMID:
22355336
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.

Inoue S, Ding H, Portilla-Arias J, Hu J, Konda B, Fujita M, Espinoza A, Suhane S, Riley M, Gates M, Patil R, Penichet ML, Ljubimov AV, Black KL, Holler E, Ljubimova JY.

Cancer Res. 2011 Feb 15;71(4):1454-64. doi: 10.1158/0008-5472.CAN-10-3093. Epub 2011 Feb 8.

PMID:
21303974
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.

Corkery B, Crown J, Clynes M, O'Donovan N.

Ann Oncol. 2009 May;20(5):862-7. doi: 10.1093/annonc/mdn710. Epub 2009 Jan 15.

PMID:
19150933
[PubMed - indexed for MEDLINE]
Free Article
4.

Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid).

Fujita M, Lee BS, Khazenzon NM, Penichet ML, Wawrowsky KA, Patil R, Ding H, Holler E, Black KL, Ljubimova JY.

J Control Release. 2007 Oct 8;122(3):356-63. Epub 2007 Jun 5.

PMID:
17630012
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.

Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S, Yin MJ.

Clin Cancer Res. 2011 Aug 15;17(16):5432-42. doi: 10.1158/1078-0432.CCR-11-0592. Epub 2011 Jun 29.

PMID:
21715568
[PubMed - indexed for MEDLINE]
Free Article
6.

Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.

Mehta R, Katta H, Alimirah F, Patel R, Murillo G, Peng X, Muzzio M, Mehta RG.

PLoS One. 2013 Jun 10;8(6):e65113. doi: 10.1371/journal.pone.0065113. Print 2013.

PMID:
23762292
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.

Ding H, Helguera G, Rodríguez JA, Markman J, Luria-Pérez R, Gangalum P, Portilla-Arias J, Inoue S, Daniels-Wells TR, Black K, Holler E, Penichet ML, Ljubimova JY.

J Control Release. 2013 Nov 10;171(3):322-9. doi: 10.1016/j.jconrel.2013.06.001. Epub 2013 Jun 12.

PMID:
23770212
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF.

Breast Cancer Res. 2012 Apr 26;14(2):R68.

PMID:
22537901
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.

Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, Lavi S, Lindzen M, Ben-Chetrit N, Sela M, Yarden Y.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1815-20. doi: 10.1073/pnas.1220763110. Epub 2013 Jan 14.

PMID:
23319610
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.

Cancer Res. 2001 Dec 15;61(24):8887-95.

PMID:
11751413
[PubMed - indexed for MEDLINE]
Free Article
11.

Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.

Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA.

Int J Oncol. 2008 Dec;33(6):1165-76.

PMID:
19020749
[PubMed - indexed for MEDLINE]
12.

Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.

Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F, Tortora G.

Clin Cancer Res. 2004 Jul 15;10(14):4858-64.

PMID:
15269162
[PubMed - indexed for MEDLINE]
Free Article
13.
14.

Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.

Sasaki T, Kitadai Y, Nakamura T, Kim JS, Tsan RZ, Kuwai T, Langley RR, Fan D, Kim SJ, Fidler IJ.

Neoplasia. 2007 Dec;9(12):1066-77.

PMID:
18084614
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A.

Neoplasia. 2012 Feb;14(2):121-30.

PMID:
22431920
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.

Liu T, Yacoub R, Taliaferro-Smith LD, Sun SY, Graham TR, Dolan R, Lobo C, Tighiouart M, Yang L, Adams A, O'Regan RM.

Mol Cancer Ther. 2011 Aug;10(8):1460-9. doi: 10.1158/1535-7163.MCT-10-0925. Epub 2011 Jun 20.

PMID:
21690228
[PubMed - indexed for MEDLINE]
Free Article
17.

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL.

J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7.

PMID:
18180460
[PubMed - indexed for MEDLINE]
18.

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM.

Mol Cancer Ther. 2001 Dec;1(2):85-94.

PMID:
12467226
[PubMed - indexed for MEDLINE]
Free Article
19.

HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer.

Yotsumoto F, Oki E, Tokunaga E, Maehara Y, Kuroki M, Miyamoto S.

Int J Cancer. 2010 Dec 1;127(11):2707-17. doi: 10.1002/ijc.25472.

PMID:
20499311
[PubMed - indexed for MEDLINE]
20.

Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.

Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placido S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2000 Nov;6(11):4343-50.

PMID:
11106252
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk